NMT Medical, AGA Medical settle
This article was originally published in The Gray Sheet
In return for full and final settlement of NMT's 1999 patent infringement suit, AGA will pay NMT $30 mil. for a nonexclusive sublicense to patent '420, which relates to NMT's CardioSeal, the two firms announced March 28. The alleged infringement affects all AGA Amplatzer occluding devices. NMT will split the settlement with inventor Lloyd Marks, MD, according to the firm. NMT competes with AGA in the patent foramen ovale occlusion market with STARFlex. Preliminary results of NMT's MIST I trial suggest a connection between patent foramen ovale closure and migraine symptoms (1"The Gray Sheet" March 20, 2006, p. 3)...
You may also be interested in...
Preliminary clinical trial data show NMT Medical's STARflex patent foramen ovale (PFO) closure device to be no more effective than placebo in completely eliminating migraine headaches, although the device did appear to improve some symptoms
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.